Business
Skye Provides 2026 Corporate Outlook
CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring Committee (DMC) meeting on December 14, 2025, continued to demonstrate favorable safety profile.CBeyond Phase 2a topline results to 52 weeks including 13-week off-therapy follow-up period expected in Q3 2026. Phase 2b (CBeyond 2) plan to be finalized in Q1; trial launch targeted for Q3 2026. SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Sky
About this update from Skye Bioscience, Inc.
[{"type":"image","alt":"Skye Bioscience, Inc.","displaySize":"","headline":null,"caption":"Skye Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":141,"url":"https://media.zenfs.com/en/globenewswire.com/90c497d694309d41a1d6fa12ddb2a61c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7pwAl2G8ZGCyG39CbcNdmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/90c497d694309d41a1d6fa12ddb2a61c","width":300,"height":141}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. ","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"CBeyond Phase 2a Data Monitoring Committee (DMC) meeting on December 14, 2025, continued to demonstrate favorable safety profile.","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"CBeyond Phase 2a topline results to 52 weeks including 13-week off-therapy follow-up period expected in Q3 2026. ","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2b (CBeyond 2) plan to be finalized in Q1; trial launch targeted for Q3 2026.","length":83,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":410,"olType":false},{"type":"text","content":"SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today provided its 2026 corporate outlook outlining planned clinical, manufacturing, and corporate milestones to advance nimacimab, Skye’s peripherally restricted CB1-inhibiting antibody.","length":413,"tagName":"p"},{"type":"text","content":"“In 2025 we generated our Phase 2a clinical data, deepened our understanding of nimacimab’s exposure-response dynamics, and built the technical foundation required to test higher doses and prepare the framework for a potential subsequent Phase 2 trial with broader clinical endpoints,” said Punit Dhillon, President & Chief Executive Officer. “In 2026, our focus and goals are straightforward: deliver additional clinical readouts from our CBeyond extension study, assess and select higher doses of nimacimab, and launch a Phase 2b study designed to evaluate multiple doses of nimacimab as a monother...